For research use only
| Cat No. | ABC-TC0918 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Product Code | QGP 1; QGP1 |
QGP-1 is a pancreatic neuroendocrine tumor cell line expressing CEA, SSTR2/5, used in pNET studies and neuroendocrine drug screening models.
QGP-1 cell line is a human pancreatic neuroendocrine tumor cell line derived from a well-differentiated pancreatic neuroendocrine tumor (pNET). These cells exhibit epithelial-like polygonal or rounded morphology and grow adherently in standard culture conditions. The line express neuroendocrine markers (synaptophysin, chromogranin A) alongside somatostatin receptors (SSTR2/SSTR5). Its transcriptional profile includes immature β/δ-cell genes (PAX4, ARX), while genomic instability manifests as mixed diploid/tetraploid populations. QGP-1 is identified as Grade 3 neuroendocrine carcinoma with a Ki-67 index of 82. 6% ± 1. 0%. Mutational analysis revealed TP53 and APC gene mutations, including a p. R2166Q mutation in APC. QGP-1 is a critical model for studying pNET biology, somatostatin signaling, and targeted therapies, despite limited in vivo tumorigenicity.
| Product Code | QGP 1; QGP1 |
| Species | Human |
| Cat.No | ABC-TC0918 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
QGP-1 cell line can serve as an in vitro cell model for neuroendocrine tumor (NET) drug development. In addition, the QGP-1 cell line is also an excellent model for studying human enterochromaffin (EC) cells. Because it highly expresses EC cell marker genes and transient receptor potential ankyrin 1 (TRPA1), it can be used to further explore the function and regulatory mechanism of TRPA1 in EC cells.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Si, Y., Kim, S., Guenter, R., Ou, J., Lu, Y., Chen, K., Zhang, J., Whitt, J., Carter, A.M., Bibb, J.A. and Jaskula-Sztul, R., 2019. Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy. bioRxiv, p.688184.
Si Y, Guan J, Xu Y, et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics. 2020;12(11):1079. Published 2020 Nov 11. doi:10.3390/pharmaceutics12111079
Herring, B., Jang, S., Whitt, J., Goliwas, K., Aburjania, Z., Dudeja, V., Ren, B., Berry, J., Bibb, J., Frost, A. and Chen, H., 2021. Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Frontiers in endocrinology, 12.
